Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Thorax
Published October 1, 2026
End of rarity: the evolving burden of interstitial lung diseases in England - trends from a natio...
October 2, 2026
Medspoke
Medspoke
ERJ Open Research
Published September 1, 2026
00:00
--:--
Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis.
October 2, 2026
Share
Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis.
https://www.medspoke.co/channel_journal?id=740&tap_id=14911
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Circulation
Published October 1, 2026
Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes: A Scientific Statement...
October 2, 2026
Why are you reporting this TALK?
